As Samsung Biologics’ contract manufacturing business continues to fire on all cylinders, the CDMO has earned a unique ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

The global bio-pharmaceutical market is projected to surge to approximately 1,400 trillion won in about two years. Bio-pharmaceuticals refer to medicines made from biological materials such as human ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. The ...

The most recent analyst rating on (BBIO) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page. According to ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. The third stock on our list is BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Russell 2000 Stocks to Buy Right Now. On January 20, Tiago Fauth from ...

This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, ...